<p>Targeting eIF3f Suppresses the Growth of Prostate Cancer Cells by Inhibiting Akt Signaling</p>

Abstract

Background: Eukaryotic initiation factor 3 (eIF3) is the largest translation initiation factor, and oncogenic roles have been discovered for its subunits, including the f subunit (ie, eIF3f), in various human cancers. However, the roles of eIF3f in the development and progression of prostate cancer (PCa) have not been reported. Materials and Methods: We performed in silico analysis to screen the expression of eIF3 subunits. Relevant shRNAs were used to knock down eIF3 subunits in 22Rv1 cells and cell proliferation was analyzed. eIF3f expression in PCa specimens was confirmed by immunohistochemistry. eIF3f knockdown was established to evaluate the effects of eIF3f on cell proliferation in vitro and in vivo. RNA-seq, bioinformatics analysis and Western blotting were applied to explore the molecular details underlying the biological function of eIF3f in PCa cells. shRNA-resistant eIF3f and myristoylated-Akt were used to rescue the effects of eIF3f disturbance on PCa cells. Results: Functional analyses confirmed that eIF3f is essential for PCa proliferation. Notably, the expression of eIF3f was found to be elevated in human PCa tissues as well as in PCa cell lines. eIF3f silencing significantly suppressed the growth of PCa cells, both in vitro and in vivo. eIF3f expression was positively correlated with Akt signaling activity in RNA-seq profiles and published prostate cohorts. Knockdown of eIF3f markedly reduced the levels of phosphorylated Akt in PCa cells. Exogenous expression of shRNA-resistant eIF3f in eIF3f knockdown cells restored Akt phosphorylation levels and cell growth. Importantly, rescue experiments revealed that ectopic expression of myristoylated-Akt partially alleviated the suppressive effects of eIF3f disturbance with respect to the growth of PCa cells. Conclusion: These results suggested that eIF3f has an oncogenic role in PCa, mediated at least partially through the regulation of Akt signaling, and that eIF3f represents a potential target for the inhibition of PCa growth and progression.

Targeting SMYD2 inhibits prostate cancer cell growth by regulating c‐Myc signaling

“…Western blot analysis was carried out as described previously 29 . The following antibodies were used in this study: SMYD2 (21290‐1‐AP; Proteintech), c‐Myc (10828‐1‐AP; Proteintech), Vinculin (A2752; Abclonal), GAPDH (ab8245; Abcam).…”

Functions and mechanisms of N6‑methyladenosine in prostate cancer (Review)

“…Luxton et al found that the oncogene metadherin collocated with YTHdc1 subnuclear spots and regulated the ability of YTHdc1 to affect Pca progression (53). Similarly, the downregulation of eIF3f expression reduces Akt levels, inhibiting PCa growth and progression (54). in some of the earliest studies of advanced Pca, researchers found that upregulated eiF3S3 gene expression was a common phenomenon, suggesting that eiF3S3 overexpression promoted tumor growth (55)(56)(57).…”